Hyperbaric Oxygen Therapy in Sickle Cell Pain (HAVOC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03412045

Recruitment Status : Not yet recruiting

First Posted : January 26, 2018

Last Update Posted : March 17, 2022

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

Jeffrey Cooper MD FAAEM, University of Nebraska

Study Description

Brief Summary:

Hyperbaric oxygen therapy in acute sickle cell pain crisis. The purpose of this study is to explore if hyperbaric oxygen therapy would decrease hospital length of stay and pain associated with acute sickle cell pain crisis. Eligibility criteria include both female and males age 19 years or older with sickle cell who are in an acute pain crisis. Exclusions include pregnancy and a sickle cell crisis complicated by any acute significant concomitant factors/conditions (i.e., acute chest syndrome, acute MI/stroke). Interventions would be 1-3 hyperbaric oxygen sessions depending on response to the therapy. Each treatment session will be approximately two hours in length. Evaluation would be through patients' self assessment via the visual analog scale for pain level before and after treatments as well as tracking length of stay in the hospital.

Condition or disease	Intervention/treatment	Phase
Vaso-occlusive Crisis Sickle Cell Anemia Crisis	Device: hyperbaric oxygen therapy	Not Applicable

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	10 participants
Allocation:	N/A
Intervention Model:	Single Group Assignment
Intervention Model Description:	a convenience sample of patients admitted to hospital for vaso-occlusive sickle cell crisis to be treated with hyperbaric oxygen in an effort to ameliorate pain and shorten the length of stay. In this sense, hyperbaric oxygen will be the intervention and used as a treatment drug.
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Hyperbaric Oxygen Therapy in Sickle Cell Pain
Estimated Study Start Date :	April 1, 2022
Estimated Primary Completion Date :	April 1, 2023
Estimated Study Completion Date :	December 1, 2023

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Sickle cell disease

MedlinePlus related topics: Oxygen Therapy

Genetic and Rare Diseases Information Center resources: Sickle Cell Anemia

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: treatment this preliminary study will be a convenience sample of patients admitted to hospital for vaso-occlusive sickle cell crisis to be treated with hyperbaric oxygen in an effort to ameliorate pain and shorten the length of stay. In this sense, hyperbaric oxygen will be used as a treatment drug. Results will be compared with historical controls	Device: hyperbaric oxygen therapy hyperbaric oxygen therapy applied to patients in vaso-occlusive crisis

Outcome Measures

Primary Outcome Measures :

100mm visual analog pain scale as used in Anesthesiology 12 2001, Vol.95, 1356-1361 [ Time Frame: change in pain scale within one hour before and after each hyperbaric treatment. scale is 0-100, 0 being no pain and 100 being maximal pain imaginable for that subject. ]
decreased pain

Secondary Outcome Measures :

hospital length of stay [ Time Frame: hospital length of stay in days (measured from day/time of admission to day/time of discharge) From date of randomization until the date of discharge or date of death from any cause, whichever came first, assessed up to 1 month" ]
days
100mm visual analog pain scale as used in Anesthesiology 12 2001, Vol.95, 1356-1361 [ Time Frame: change in pain scale between admission and discharge. scale: 0-100, 0=no pain, 100=maximal pain imaginable for that subject. From date of admit until the date of last documented progression prior to discharge. an expected average of up to 3 days ]
decreased pain

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	19 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

>19 years old patients who
present with sickle cell disease who are currently in uncomplicated sickle cell crisis present at time of admission from the emergency department at UNMC

Exclusion Criteria:

< 19 years old,
pregnant female,
complicated sickle cell crisis present (i.e., concomitant MI, stroke, acute chest syndrome at time of presentation)

Contacts and Locations

No Contacts or Locations Provided

More Information

Layout table for additonal information

Responsible Party:	Jeffrey Cooper MD FAAEM, director, hyperbaric medicine, University of Nebraska
ClinicalTrials.gov Identifier:	NCT03412045
Other Study ID Numbers:	IRB#003-17-FB
First Posted:	January 26, 2018 Key Record Dates
Last Update Posted:	March 17, 2022
Last Verified:	March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	Undecided

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	Yes
Product Manufactured in and Exported from the U.S.:	Yes

Additional relevant MeSH terms:

Layout table for MeSH terms

Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia	Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn

To Top